- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07628959
Innovative Sleep Quality Analysis Software Compared With Polysomnography (LUNA)
Pilot Study of Innovative Sleep Quality Analysis Software Compared With Polysomnography
To diagnose sleep disorders, practitioners primarily use polysomnography (PSG), a precise but costly, cumbersome method that is limited to a single observation. This does not allow for longitudinal monitoring of sleep habits in real-world conditions. An alternative is offered with the C. Santé software receiving information from sensors installed on medical bed. This software analyzes cardiorespiratory parameters and sleep phases without disturbing the patient, enabling continuous and comfortable monitoring. A preliminary study aims to validate the reliability of the C. Santé software analysis, by comparing it to the PSG analysis, considered the gold standard.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Bruno STIMMESSE, MD
- Telefonnummer: +33 (0)4 82 77 48 58
- E-post: bstimmesse@mutualite-loire.com
Studera Kontakt Backup
- Namn: Clara PFENNINGER, CDP
- Telefonnummer: +33 (0)4 77 12 08 26
- E-post: clara.pfenninger@chu-st-etienne.fr
Studieorter
-
-
-
Saint-Etienne, Frankrike, 42000
- Clinique Mutualiste
-
Huvudutredare:
- Bruno STIMMESSE, MD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Adult patients aged over 18 years.
- Patients affiliated with or beneficiaries of a social security system.
- Patients capable of completing all aspects of the study.
- Patients who have signed informed consent for participation in the study
Exclusion Criteria:
- pregnancy
- Patients suffering from an acute bacterial, fungal, or viral infection.
- Patients unable to tolerate the placement of the PSG.
- Patients with psychiatric disorders incompatible with the constraints associated with the need to spend two nights at the clinic.
- restless legs syndrome
- Presence of a cardiac pacemaker.
- Cardiac arrhythmia problems (e.g., complete arrhythmia).
- Known and treated sleep disorders (e.g., sleep apnea syndrome) or uncontrolled chronic insomnia.
- Diagnosed dementia.
- Simultaneous participation in other research studies.
- Use of medications that could alter sleepiness, including:
- Sedative-hypnotics.
- Neuroleptics.
- Antidepressants.
- Anxiolytics.
- H1 antihistamines.
- Antiepileptics.
- Opiates and opioid analgesics.
- Patients under legal guardianship or curatorship.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Diagnostisk
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Polysomnography
The patients will spend two consecutive nights on the bed equipped with C. Santé software which is also equipped with traditional polysomnography. |
Patients visit the Sleep Unit at the Clinique Mutualiste for sleep disorders. During their consultation with the doctor, a polysomnography scheduled over two consecutive nights is proposed (this applies to any diagnosis of sleep disorders). At that time, they are also invited to participate in the study. After receiving information about the study and signing the consent form, the patient returns for their two consecutive nights equipped with PSG, which they spend on the bed equipped with sensors transmitting information to C. Santé software. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
The agreement in sleep efficiency measurement performed C. Santé software compared to polysomnography (PSG).
Tidsram: "Up to 3 months after inclusion
|
The study's objective will be met if the sleep efficiency measured by PSG and that calculated from C. Santé software differ by no more than 10%. This means the device will be considered effective if there is at least 90% agreement between PSG and the C. Santé software. |
"Up to 3 months after inclusion
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Accuracy of RR interval measurement
Tidsram: Up to 3 months after inclusion
|
Determined from the ECG trace of the PSG compared to the C. Santé software |
Up to 3 months after inclusion
|
|
Accuracy of sleep phase duration measurement
Tidsram: Up to 3 months after inclusion
|
Comparing PSG-calculated durations for sleep stages (N1: light slowwave sleep, N2: intermediate slow-wave sleep, N3: deep slow-wave sleep, REM: rapid eye movement sleep) to the C. Santé software calculation for slow-wave sleep (N) and REM. |
Up to 3 months after inclusion
|
|
Accuracy of respiratory rate measurement
Tidsram: Up to 3 months after inclusion
|
Comparing C. Santé software measurements to nasal cannula measurements from PSG (analyzed in 30-second intervals) |
Up to 3 months after inclusion
|
|
Accuracy in positional data
Tidsram: Up to 3 months after inclusion
|
Comparing the time spent lying on the back or side and the number of position changes as calculated by PSG (via a thoracic accelerometer) and by C. Santé software. |
Up to 3 months after inclusion
|
|
Differences in measurements across two consecutive nights
Tidsram: Up to 3 months after inclusion
|
Differences in measurements across two consecutive nights |
Up to 3 months after inclusion
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Studiestol: Frédéric ROCHE, MD PhD, CHU de Saint-Etienne
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 25CH123
- ANSM (Annan identifierare: 2026-A00074-47)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .